Skip to content
DataLookout
Menu

NCT06857175

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 37 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 508 to confirmed 515
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Minor Study title revisedv5
  3. Minor Enrollment target: 674 to 508v4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria shortened, about 4 words
    • Start date changed from estimate of Mar 2025 to Mar 25, 2025
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS)
Timeframe: Up to approximately 24 months
Overall survival (OS)
Timeframe: Up to approximately 24 months

Secondary (5)

Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DOR)
Treatment Emergent Adverse Event (TEAE)
Anti-drug antibody (ADA)

Arms and interventions

BL-B01D1Experimental

Participants receive BL-B01D1 in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Docetaxel or PaclitaxelActive comparator

Participants receive Docetaxel or Paclitaxel in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Drugs: BL-B01D1, Docetaxel or Paclitaxel

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China